



11:25-12:10 **Lorlatinib: Clinical Data and Implications for the Sequential Therapy in Anaplastic Lymphoma Kinase+ Non-Small Cell Lung Cancer**

## Benjamin Solomon

Head of Lung Medical Oncology, Peter MacCallum Cancer Centre  
Sir Peter MacCallum Department of Oncology, University of Melbourne  
Specialty: Medical Oncologist

### [Recent Activities]

- Clinical and Translational Research in Lung Cancer
  - with focus on Development of Targeted Therapies in Lung Cancer
- Development of Novel ALK Inhibitors , Including the Phase I through to Phase III Clinical Trials with the Crizotinib and Lorlatinib that led to its Approval in the Treatment of ALK-rearranged NSCLC, and other Novel Targeted Therapies and Immunotherapies for Patients with NSCLC.
- Scientific Chair of the Thoracic Oncology Group of Australia (TOGA).

### [Research Interests]

- Clinical and Translational Research in Lung Cancer, the Thoracic Oncology